Uncategorized

Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up

Published

on

The FDA greenlit 26 novel therapies in the first half of 2026, including four for cancer and six for orphan indications. Meanwhile, AstraZeneca and Johnson and Johnson took home a combined 11 of the agency’s 79 total approvals, including supplemental nods.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version